SGMO - Sangamo Therapeutics Inc Stock Price, Fair Value and News

0.49USD-0.03 (-5.77%)Market Closed

Market Summary

USD0.49-0.03

Market Closed

-5.77%

SGMO Stock Price

View Fullscreen

SGMO RSI Chart

SGMO Valuation

Market Cap

87.7M

Price/Earnings (Trailing)

-0.34

Price/Sales (Trailing)

0.5

EV/EBITDA

-0.17

Price/Free Cashflow

-0.36

SGMO Price/Sales (Trailing)

SGMO Profitability

EBT Margin

-149.18%

Return on Equity

-311.06%

Return on Assets

-155.96%

Free Cashflow Yield

-280.61%

SGMO Fundamentals

SGMO Revenue

Revenue (TTM)

176.2M

Rev. Growth (Yr)

-92.5%

Rev. Growth (Qtr)

-78.27%

SGMO Earnings

Earnings (TTM)

-257.8M

Earnings Growth (Yr)

-16.01%

Earnings Growth (Qtr)

42.11%

Breaking Down SGMO Revenue

Last 7 days

-3.7%

Last 30 days

-25.7%

Last 90 days

18.2%

Trailing 12 Months

-68.5%

How does SGMO drawdown profile look like?

SGMO Financial Health

Current Ratio

1.98

SGMO Investor Care

Shares Dilution (1Y)

6.19%

Diluted EPS (TTM)

-1.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	241.0M	218.5M	201.4M	176.2M
2022	112.7M	114.2M	112.1M	111.3M
2021	131.4M	137.7M	108.5M	110.7M
2020	107.4M	111.4M	147.2M	118.2M
2019	79.9M	76.0M	74.4M	102.4M
2018	45.8M	58.9M	70.7M	84.5M
2017	18.9M	23.4M	32.4M	36.6M
2016	30.0M	25.3M	19.6M	19.4M
2015	51.2M	49.2M	45.4M	39.5M
2014	27.6M	31.1M	37.8M	45.9M
2013	23.0M	25.4M	26.2M	24.1M
2012	11.4M	14.4M	17.5M	21.7M
2011	16.4M	11.3M	10.3M	10.3M
2010	0	21.7M	21.3M	20.8M
2009	0	0	0	22.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sangamo Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 25, 2024	duraibabu prathyusha	sold (taxes)	-3,901	1.13	-3,453	svp, chief financial officer
Feb 25, 2024	pooler amy	sold (taxes)	-2,778	1.13	-2,459	vp, head of research
Feb 25, 2024	macrae sandy	sold (taxes)	-27,297	1.13	-24,157	president, ceo and director
Feb 25, 2024	willoughby scott b.	sold (taxes)	-3,901	1.13	-3,453	svp, gen. counsel & secretary
Feb 25, 2024	dubois-stringfellow nathalie	sold (taxes)	-5,661	1.13	-5,010	svp-chief development officer
Feb 24, 2024	willoughby scott b.	sold (taxes)	-4,948	1.13	-4,379	svp, gen. counsel & secretary
Feb 24, 2024	macrae sandy	sold (taxes)	-18,209	1.13	-16,115	president, ceo and director
Feb 24, 2024	dubois-stringfellow nathalie	sold (taxes)	-6,185	1.13	-5,474	svp-chief development officer
Feb 24, 2024	pooler amy	sold (taxes)	-2,496	1.13	-2,209	vp, head of research
Feb 24, 2024	duraibabu prathyusha	sold (taxes)	-6,185	1.13	-5,474	svp, chief financial officer

Which funds bought or sold SGMO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	NATIONS FINANCIAL GROUP INC, /IA/ /ADV	reduced	-2.74	1,590	9,550	-%
Apr 23, 2024	BFSG, LLC	new	-	2,457	2,457	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-60.23	-4,000	3,000	-%
Apr 23, 2024	Venturi Wealth Management, LLC	unchanged	-	64.00	336	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	99.00	328	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	reduced	-17.8	124	8,947	-%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-40,773	-	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	9,349	9,349	-%
Apr 19, 2024	ALBION FINANCIAL GROUP /UT	unchanged	-	26.00	135	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%

Are Funds Buying or Selling SGMO?

Are funds buying SGMO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SGMO

No. of Funds

Unveiling Sangamo Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 13, 2024	vanguard group inc	7.10%	12,598,994	SC 13G/A
Feb 12, 2024	biogen inc.	75%	14,652,466	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.9%	14,095,865	SC 13G/A
Jan 22, 2024	state street corp	1.53%	2,708,368	SC 13G/A
Oct 10, 2023	wasatch advisors lp	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.57%	14,045,609	SC 13G/A
Feb 09, 2023	wasatch advisors inc	-	0	SC 13G/A
Feb 07, 2023	state street corp	5.97%	9,788,884	SC 13G/A

Recent SEC filings of Sangamo Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	PRE 14A	PRE 14A
Mar 25, 2024	424B5	Prospectus Filed
Mar 25, 2024	8-K	Current Report
Mar 13, 2024	10-K	Annual Report
Mar 13, 2024	8-K	Current Report
Feb 27, 2024	4	Insider Trading
Feb 27, 2024	4	Insider Trading

Peers (Alternatives to Sangamo Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Sangamo Therapeutics Inc News

Latest updates

Sangamo Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-78.3%	2,042,000	9,398,000	6,835,000	157,957,000	27,230,000	26,460,000	29,378,000	28,231,000	27,986,000	28,563,000	27,872,000	26,280,000	25,800,000	57,763,000	21,553,000	13,076,000	54,851,000	21,958,000	17,548,000	8,071,000	26,837,000
Operating Expenses	-44.6%	64,101,000	115,806,000	130,407,000	139,923,000	82,622,000	81,354,000	75,112,000	73,492,000	67,885,000	76,999,000	76,572,000	72,582,000	69,232,000	61,464,000	59,450,000	57,598,000	53,382,000	51,206,000	51,052,000	51,968,000	47,609,000
S&GA Expenses	-5.9%	13,099,000	13,918,000	16,014,000	18,136,000	16,443,000	16,238,000	15,093,000	14,908,000	16,084,000	14,501,000	16,486,000	16,148,000	16,874,000	16,177,000	17,927,000	16,119,000	15,053,000	14,918,000	14,597,000	17,118,000	14,355,000
R&D Expenses	-11.2%	50,706,000	57,089,000	63,046,000	63,216,000	66,179,000	65,116,000	60,019,000	58,584,000	51,801,000	62,498,000	60,086,000	56,434,000	52,358,000	45,287,000	41,523,000	41,479,000	38,329,000	36,288,000	36,455,000	34,850,000	33,254,000
EBITDA Margin	-19.3%	-1.41	-1.18	-0.87	-0.47	-1.62	-1.49	-1.46	-1.49	-1.52	-1.04	-0.82	-0.87	-	-	-	-	-	-	-	-	-
Income Taxes	-121.4%	-272,000	1,270,000	-6,264,000	194,000	238,000	30,000	82,000	100,000	-73,500	100,000	24,000	262,000	108,000	237,000	-	-	-	-	-	-	-
Earnings Before Taxes	41.1%	-60,567,000	-102,893,000	-120,770,000	21,327,000	-51,714,000	-53,125,000	-43,091,000	-43,919,000	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-18.3%	-1.49	-1.26	-0.94	-0.53	-1.72	-1.59	-1.56	-1.58	-1.61	-1.11	-0.88	-0.92	-	-	-	-	-	-	-	-	-
Net Income	42.1%	-60,295,000	-104,163,000	-114,506,000	21,133,000	-51,973,000	-53,155,000	-43,173,000	-43,977,000	-37,488,000	-47,688,000	-47,174,000	-45,933,000	-40,604,000	-1,550,000	-35,929,000	-42,913,000	4,555,000	-27,307,000	-30,284,000	-42,150,000	-18,664,000
Net Income Margin	-18.1%	-1.46	-1.24	-0.91	-0.53	-1.73	-1.59	-1.51	-1.57	-1.61	-1.67	-0.98	-0.94	-	-	-	-	-	-	-	-	-
Free Cashflow	-6.3%	-53,209,000	-50,037,000	-66,251,000	-76,500,000	-64,523,000	-58,031,000	-59,430,000	-61,814,000	-55,572,000	-64,627,000	-59,830,000	-76,500,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-24.8%	165	220	325	441	563	594	617	654	722	772	835	877	939	964	895	584	638	640	673	543	590
Current Assets	-36.1%	94.00	148	160	227	300	337	343	340	399	447	554	607	660	700	679	371	405	384	462	363	411
Cash Equivalents	-20.0%	45.00	57.00	67.00	78.00	100	95.00	118	120	180	177	170	123	133	259	467	86.00	82.00	114	169	81.00	144
Net PPE	-5.5%	27.00	28.00	61.00	60.00	64.00	56.00	53.00	52.00	52.00	51.00	50.00	45.00	41.00	35.00	34.00	31.00	30.00	27.00	21.00	18.00	79.00
Goodwill	-	-	-	-	-	38.00	35.00	37.00	39.00	40.00	41.00	42.00	41.00	43.00	41.00	39.00	39.00	39.00	38.00	40.00	39.00	40.00
Liabilities	-2.8%	82.00	85.00	91.00	105	268	285	299	320	347	366	390	408	441	443	383	190	205	221	228	214	223
Current Liabilities	-1.5%	48.00	48.00	54.00	58.00	112	122	120	119	128	132	137	133	144	124	94.00	62.00	70.00	81.00	82.00	91.00	79.00
Shareholder's Equity	-38.6%	83.00	135	234	336	295	309	318	335	375	406	445	469	497	521	511	394	433	419	446	329	367
Retained Earnings	-4.5%	-1,406	-1,346	-1,241	-1,127	-1,148	-1,096	-1,043	-1,000	-956	-918	-871	-823	-777	-737	-735	-699	-656	-661	-634	-603	-562
Additional Paid-In Capital	0.4%	1,492	1,486	1,480	1,467	1,450	1,423	1,373	1,340	1,334	1,324	1,313	1,292	1,269	1,256	1,248	1,097	1,091	1,084	1,079	934	930
Shares Outstanding	0.5%	178	177	174	169	167	151	147	146	145	145	144	143	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-0.94	-0.87	-0.53	-0.25	0.00	0.00	0.00	1.00	1.00	1.00
Float	-	-	-	229	-	-	-	633	-	-	-	1,734	-	-	-	1,262	-	-	-	1,245	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-6.9%	-50,538	-47,293	-60,711	-66,300	-57,049	-53,618	-53,985	-58,975	-52,714	-59,420	-52,567	-68,550	-4,295	33,067	159,993	-18,890	-20,816	-38,874	-39,593	-45,119	-40,161
Share Based Compensation	-1.3%	6,107	6,189	6,790	8,277	8,248	7,793	7,918	7,691	8,076	7,873	9,483	7,524	6,642	6,682	6,764	5,620	5,239	4,701	4,867	4,523	4,303
Cashflow From Investing	0.2%	37,708	37,627	42,468	35,728	42,613	-13,462	28,429	1,705	52,635	60,976	89,299	45,289	-130,458	-242,497	77,608	23,720	-16,402	-16,217	-12,383	-14,799	62,835
Cashflow From Financing	267.0%	167	-100	6,519	8,002	19,535	43,818	22,874	-1,567	2,112	5,492	10,019	15,235	6,919	1,616	144,156	409	1,219	704	139,890	216	1,566

SGMO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Revenues	$ 176,232,000	$ 111,299,000	$ 110,701,000
Operating expenses:
Research and development	234,057,000	249,898,000	230,819,000
General and administrative	61,167,000	62,682,000	63,219,000
Impairment of goodwill and indefinite-lived intangible assets	89,485,000	0	0
Impairment of long-lived assets	65,528,000	0	0
Total operating expenses	450,237,000	312,580,000	294,038,000
Loss from operations	(274,005,000)	(201,281,000)	(183,337,000)
Interest and other income, net	11,102,000	9,432,000	5,346,000
Loss before income taxes	(262,903,000)	(191,849,000)	(177,991,000)
Income tax (benefit) expense	(5,072,000)	429,000	306,000
Net loss	(257,831,000)	(192,278,000)	(178,297,000)
Net loss attributable to non-controlling interest	0	0	(11,000)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders	$ (257,831,000)	$ (192,278,000)	$ (178,286,000)
Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)	$ (1.48)	$ (1.25)	$ (1.23)
Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)	$ (1.48)	$ (1.25)	$ (1.23)
Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)	174,444	154,345	144,568
Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)	174,444	154,345	144,568

SGMO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 45,204	$ 100,444
Marketable securities	35,798	177,188
Interest receivable	403	794
Accounts receivable	923	3,678
Prepaid expenses and other current assets	12,000	18,223
Total current assets	94,328	300,327
Marketable securities, non-current	0	29,845
Property and equipment, net	26,874	63,531
Intangible assets	0	50,729
Goodwill	0	37,552
Operating lease right-of-use assets	25,991	62,002
Other non-current assets	16,627	17,023
Restricted cash	1,500	1,500
Total assets	165,320	562,509
Current liabilities:
Accounts payable	15,259	22,418
Accrued compensation and employee benefits	8,918	21,506
Other accrued liabilities	23,554	16,007
Deferred revenues	0	51,780
Total current liabilities	47,731	111,711
Deferred revenues, non-current	0	109,377
Long-term portion of lease liabilities	33,515	38,986
Deferred income tax	0	6,270
Other non-current liabilities	1,187	1,207
Total liabilities	82,433	267,551
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, and no shares issued or outstanding	0	0
Common stock, $0.01 par value; 640,000,000 shares authorized; 178,133,548 and 166,793,320 shares issued and outstanding at December 31, 2023 and 2022, respectively	1,781	1,668
Additional paid-in capital	1,492,077	1,450,239
Accumulated deficit	(1,406,376)	(1,148,545)
Accumulated other comprehensive loss	(4,595)	(8,404)
Total stockholders’ equity	82,887	294,958
Total liabilities and stockholders’ equity	$ 165,320	$ 562,509

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

CEO	Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
WEBSITE	sangamo.com
INDUSTRY	Biotechnology
EMPLOYEES	478

Sangamo Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Sangamo Therapeutics Inc? What does SGMO stand for in stocks?

SGMO is the stock ticker symbol of Sangamo Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sangamo Therapeutics Inc (SGMO)?

As of Tue Apr 23 2024, market cap of Sangamo Therapeutics Inc is 93.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGMO stock?

You can check SGMO's fair value in chart for subscribers.

What is the fair value of SGMO stock?

You can check SGMO's fair value in chart for subscribers. The fair value of Sangamo Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sangamo Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SGMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sangamo Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SGMO is over valued or under valued. Whether Sangamo Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sangamo Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGMO.

What is Sangamo Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, SGMO's PE ratio (Price to Earnings) is -0.36 and Price to Sales (PS) ratio is 0.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sangamo Therapeutics Inc's stock?

In the past 10 years, Sangamo Therapeutics Inc has provided -0.279 (multiply by 100 for percentage) rate of return.